Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study

Table 1 Demographic and clinical characteristics of the studied population stratified according to disease type

Characteristic	Crohn's disease	Ulcerative colitis	P value
Included patients	141	133
Sex, % males	54.6%	59.4%	0.42
Mean age at IBD diagnosis in yr	33.2 ± 14.2	28.8 ± 14.4	0.01
Disease location
Upper GI-L4	5.7%
Small bowel-L1	17.8%
Ileum + colon-L3	61%
Pancolitis-L2	15.6%	61%
Left-sided colitis		37.5%
Proctosigmoiditis		1.5%
Perianal	7.8%
Phenotype
Inflammatory	56.7%
Stenosing	24.8%
Fistulizing	7.8%
Fistulizing + Stenosing	5.7%
Inflammatory + Fistulizing	2.2%
Inflammatory + Stenosing	2.8%
Reasons for AZA introduction			0.23
Steroid-dependent	95.8%	90.2%
Steroid-refractory	2.1%	5.3%
Steroid intolerance	0.7%	3%
Other reasons	1.4%	1.5%
Comorbidities
PSC	0%	2.3%	0.07
Autoimmune rheumatic diseases	7.8%	3.0%	0.08
Cardiac involvement	4.3%	7.5%	0.25

AZA: Azathioprine; IBD: Inflammatory bowel disease; PSC: Primary sclerosing cholangitis.